Perioperative medicine & outcomes

Postoperative Pulmonary Complications in the ENIGMA II Trial: A Post Hoc Analysis

AnesthesiologyPublished Post hoc analysis of the ENIGMA II randomised trial

Primary result · AtelectasisResult — go to the resultOdds ratio 0.77 95% CI 0.62–0.97

Authors' conclusion

In contrast to the earlier ENIGMA trial, nitrous oxide anesthesia in the ENIGMA II trial was associated with a lower incidence of lung atelectasis, but not pneumonia, after major surgery.

Study context

Population
Major surgery patients recruited to the Australian cohort of ENIGMA IIrandomized patients included
Participants
2,328 patients
Comparison
Nitrous oxide vs nitrous oxide-free anaesthesia at FiO2 0.3
  • Nitrous oxiden = 1,169
  • Nitrous oxide-freen = 1,159reference
Primary endpoint
Atelectasis (lung atelectasis or collapse on chest radiology)
Methodological detailsoutcome assessment blinded to allocation, intention-to-treat, multicentre (10 Australian hospitals)
  • Outcome assessment blinded to allocation
  • Intention-to-treat
  • Multicentre (10 Australian hospitals)

Primary result

Atelectasis

Odds ratio

0.77

95% CI 0.62–0.97

P = 0.023

Events by treatment group

Nitrous oxide vs Nitrous oxide-free
OR 0.77 (95% CI 0.62–0.97); P = 0.023

As reported in the abstract

Secondary outcomes

Pneumonia (diagnostic chest radiology report with fever, leukocytosis, or positive sputum culture)

No difference in pneumonia incidence
  • Intention to treat

Combined pulmonary complications

No difference in combined pulmonary complications
  • Intention to treat

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Postoperative Pulmonary Complications in the ENIGMA II Trial: A Post Hoc Analysis. Anesthesiology. Published 16 January 2023. doi:10.1097/aln.0000000000004497

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.